Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Recruiting
Observational Study
Rheumatoid Arthritis
Interstitial Lung Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Observational
- Participants needed
- 450 (estimated)
- Sponsor
- University of Colorado, Denver · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression.
The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic feature…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria
* 18 years of age or older
Exclusion Criteria:
* Prior medication treatment specifically for RA-ILD
* Inability to give informed consent
* Pregnant women
Contacts